Drug profile · INN
tivozanib hydrochloride
FOTIVDA
tivozanib hydrochloride (FOTIVDA) is a vascular endothelial growth factor receptor inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — tivozanib hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
tivozanib hydrochloride (FOTIVDA) is a vascular endothelial growth factor receptor inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Vascular endothelial growth factor receptor inhibitor
Primary target: Platelet-derived growth factor receptor beta
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is tivozanib hydrochloride?
tivozanib hydrochloride (FOTIVDA) is a vascular endothelial growth factor receptor inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for tivozanib hydrochloride?
FOTIVDA is a marketed brand name for tivozanib hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tivozanib hydrochloride?
tivozanib hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.